Jefferies Adjusts Price Target on Amgen to $380 From $375
HSBC Raises Price Target on Eli Lilly to $1,100 From $880, Maintains Buy Rating
TD Cowen Raises Price Target on Eli Lilly to $1,050 From $850
Goldman Sachs Adjusts Price Target on Eli Lilly to $812 From $793
Nomura Adjusts Innovent Biologics' Price Target to HK$55.87 From HK$55.31, Keeps at Buy
Eli Lilly and Co Analyst Ratings
Eli Lilly & Co (LLY) Gets a Buy From Barclays
UBS Raises Price Target on Eli Lilly to $1,100 From $910, Maintains Buy Rating
Amgen Analyst Ratings
Berenberg Maintains Buy on Eli Lilly and Co, Raises Price Target to $1000
Morgan Stanley Adjusts Price Target on Amgen to $303 From $310
Berenberg Adjusts Price Target on Eli Lilly & Co. to $1,000 From $850, Maintains Buy Rating
Novo Nordisk (0QIU) Receives a Buy From J.P. Morgan
Eli Lilly and Co Analyst Ratings
Deutsche Numis Reaffirms Their Hold Rating on AstraZeneca (AZN)
Barclays Sticks to Its Buy Rating for AstraZeneca (AZN)
AstraZeneca: Strong Sales Growth and Upward Guidance Potential Justify Buy Rating
Barclays Remains a Buy on Eli Lilly & Co (LLY)
Eli Lilly and Co Analyst Ratings
Berenberg Bank Keeps Their Buy Rating on AstraZeneca (AZN)